Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 12/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 12/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 11/20 | 0.46 |
| ▸ | FDPS | P14324 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5243105 | 0.94 | — | — | |
| SCHEMBL27467455 | 0.84 | SLC6A2 (0.49) | SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL21567213 | 0.78 | SLC6A2 (0.49) | SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL1547848 | 0.77 | SLC6A2 (0.47) | SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL19417440 | 0.77 | SLC6A2 (0.47) | SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL5244582 | 0.76 | — | — | |
| SCHEMBL3478050 | 0.75 | SLC6A2 (0.46) | SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL13510425 | 0.75 | SLC6A2 (0.46) | SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL12386911 | 0.75 | SLC6A2 (0.46) | SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL19003938 | 0.75 | SLC6A2 (0.46) | SLC6A2SLC6A3SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1569638-B1 | AMINOALKOXYINDOLES AS 5-HT6-RECEPTOR LIGANDS FOR THE TREATMENT OF CNS-DISORDERS | HOFFMANN LA ROCHE (CH) | 2007-09-05 | — | — | EP | disclosed |
| US-7084169-B2 | Aminoalkoxyindoles and methods of use | ROCHE PALO ALTO LLC (US) | 2006-08-01 | — | — | US | disclosed |
| EP-1569638-A1 | AMINOALKOXYINDOLES AS 5-HT6-RECEPTOR LIGANDS FOR THE TREATMENT OF CNS-DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-09-07 | — | — | EP | disclosed |
| US-20040132799-A1 | Aminoalkoxyindoles and methods of use | ROCHE PALO ALTO LLC (US) | 2004-07-08 | — | — | US | disclosed |
| WO-2004050085-A1 | AMINOALKOXYINDOLES AS 5-HT6-RECEPTOR LIGANDS FOR THE TREATMENT OF CNS-DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040132799-A1 | Aminoalkoxyindoles and methods of use | HTR3C, HTR2C, CYP3A5 | SLC6A2 161/4885SLC6A3 119/4885SLC6A4 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.